Ligand Pharmaceuticals Incorporated Contracts & Agreements

Severance Agreement and General Release dated as of August 2, 2024, between Ligand Pharmaceuticals Incorporated and Mr. Korenberg (Filed With SEC on November 8, 2024)

Agreement on the Acquisition of Stocks in Apeiron Biologics AG entered on July 8, 2024, between Ligand Pharmaceuticals Incorporated and the sellers (Filed With SEC on August 7, 2024)

First Amendment to Credit Agreement, dated as of July 8, 2024, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors, the Lenders, and Citibank,... (Filed With SEC on August 7, 2024)

Purchase and Sale Agreement, dated May 6, 2024, byand among Ligand Pharmaceuticals Incorporated,Agenus Inc., Agenus Royalty Fund, LLC, and AgenusHoldings 2024, LLC (Filed With SEC on August 7, 2024)

Amendment to 2022 Employee Inducement Plan (Filed With SEC on February 29, 2024)

Amendment No. 1 to Development Funding and Royalties Agreement, dated as of May 22, 2020, by and between the Company and Palvella Therapeutics, Inc (Filed With SEC on February 29, 2024)

Amendment No. 2 to Development Funding and Royalties Agreement, dated as of November 29, 2023, by and between the Company and Palvella Therapeutics, Inc (Filed With SEC on February 29, 2024)

Director Compensation and Stock Ownership Policy, as amended and restated effective August 4, 2023 (Filed With SEC on August 9, 2023)

Director Compensation and Stock Ownership Policy, as amended and restated effective April 19, 2023 (Filed With SEC on May 8, 2023)

Form of Change in Control Severance Agreement (Filed With SEC on May 8, 2023)

Amended and Restated Severance Plan, effective November 1, 2022 (Filed With SEC on February 28, 2023)

Director Compensation and Stock Ownership Policy, as amended and restated, effective April 13, 2020 (Filed With SEC on February 28, 2023)

Separation Agreement , effective December 12, 2022, by and between Ligand Pharmaceuticals Incorporated and John Higgins (Filed With SEC on February 28, 2023)

Severance Agreement, effective December 5, 2022, by and between Ligand Pharmaceuticals Incorporated and Todd C. Davis (Filed With SEC on February 28, 2023)

Amended and Restated Employee Matters Agreement, dated as of August 18, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. (f/k/a OmniAb, Inc.),... (Filed With SEC on November 8, 2022)

Tax Matters Agreement, dated as of November 1, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. and OmniAb, Inc (Filed With SEC on November 4, 2022)

2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Form of Stock Option Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Form of Restricted Stock Unit Award Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Form of Performance-Based Restricted Stock Unit Award Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 28, 2022)

Lease, dated June 8, 2021, between the Company and Emery Station Office II, LLC (Filed With SEC on February 28, 2022)

Description of Registered Securities (Filed With SEC on February 24, 2021)

2002 Stock Incentive Plan (as amended and restated effective December 15, 2020) (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Barclays Bank PLC (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on February 24, 2021)

Supply agreement, dated December 22, 2015, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc (Filed With SEC on February 24, 2021)

Contingent Value Rights Agreement, dated as of September 30, 2020, by and between Ligand Pharmaceuticals Incorporated and American Stock Transfer & Trust Company, LLC (Filed With SEC on November 6, 2020)

Amendment to Supply Agreement, dated September 21, 2020, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc., which amends that certain Supply Agreement, dated... (Filed With SEC on November 6, 2020)

Agreement and Plan of Merger among Ligand Pharmaceuticals Incorporated, xCella Biosciences, Inc. and other persons, dated September 8, 2020 (Filed With SEC on September 10, 2020)

Agreement and Plan of Merger among Ligand Pharmaceuticals Incorporated, Taurus Biosciences, LLC and other persons, dated September 9, 2020 (Filed With SEC on September 10, 2020)

Contingent Value Rights Agreement between Ligand Pharmaceuticals Incorporated and Vaughn Smider, as Members Representative (regarding Taurus Biosciences, LLC acquisition), dated... (Filed With SEC on September 10, 2020)

Commercial License Agreement between Taurus Biosciences, LLC and Minotaur Therapeutics, Inc., dated September 9, 2020 (Filed With SEC on September 10, 2020)

Agreement and Plan of Merger, dated as of August 10, 2020, by and among Pfenex, Inc., Ligand Pharmaceuticals Incorporated and Pelican Acquisition Sub, Inc (Filed With SEC on August 11, 2020)

Asset Purchase Agreement, dated February 11, 2020, (as amended on April 1, 2020), by and among the Registrant, Icagen Inc., Icagen Corp., XRPro Sciences, Inc. and Caldera... (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Barclays Bank PLC (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on May 8, 2020)

Description of Registered Securities (Filed With SEC on February 27, 2020)

Amended and Restated Director Compensation and Stock Ownership Policy, effective March 28, 2019 (Filed With SEC on February 27, 2020)

Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 27, 2020)

Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc. and Acrotech Biopharma LLC (as successor-in-interest to Spectrum... (Filed With SEC on August 8, 2019)

Asset Purchase Agreement, dated March 5, 2019, by and among Ligand Pharmaceuticals Incorporated and RPI Finance Trust (Filed With SEC on March 5, 2019)

Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc (Filed With SEC on February 28, 2019)

Rule 2.7 Announcement issued by Ligand Holdings UK Ltd., dated August 9, 2018 (Filed With SEC on August 9, 2018)

Cooperation Agreement, dated August 9, 2018, by and between Vernalis plc and Ligand Holdings UK Ltd (Filed With SEC on August 9, 2018)

Break Fee Agreement, dated August 9, 2018, by and between Vernalis plc and Ligand Holdings UK Ltd (Filed With SEC on August 9, 2018)

Supplemental Indenture, dated as of February 20, 2018, between the Company and Wilmington Trust, National Association, as trustee (Filed With SEC on July 30, 2018)

LIGAND PHARMACEUTICALS INCORPORATED AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 22, 2018 0.75% Convertible Senior Notes due 2023 TABLE OF... (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Warrant Transaction (Filed With SEC on May 22, 2018)

[Signature Page Follows] (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Goldman Sachs & Co. LLC and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Amendment No. 5 to Sublicense Agreement, dated March 20, 2018, among the Company, Pharmacopeia, LLC and Retrophin, Inc (Filed With SEC on May 9, 2018)

License Agreement, dated March 5, 2018, by and between the Company and Roivant Sciences GmbH (Filed With SEC on May 9, 2018)

Agreement and Plan of Merger, dated as of October 4, 2017, by and among Ligand Pharmaceuticals Incorporated, Eagle Acquisition, Inc., Crystal Bioscience, Inc. and Shareholder... (Filed With SEC on October 4, 2017)

Third Amendment to Loan and Security Agreement (Filed With SEC on May 9, 2017)

LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective March [ ], 2014) I. DIRECTOR COMPENSATION (Filed With SEC on November 14, 2016)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on May 9, 2016)

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on May 9, 2016)

Consent of Independent Registered Public Accounting Firm (Filed With SEC on March 22, 2016)

AGREEMENT AND PLAN OF MERGER BY AND AMONG LIGAND PHARMACEUTICALS INCORPORATED, SCHRADER 1 ACQUISITION, INC., SCHRADER 2 ACQUISITION, INC., OPEN MONOCLONAL TECHNOLOGY, INC., OMT,... (Filed With SEC on December 18, 2015)

LEASE 3911/3931 SVB,LLC, a California limited liability company as Landlord, and LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation, as Tenant. 3911Sorrento Valley... (Filed With SEC on November 10, 2015)

AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT (Filed With SEC on November 9, 2015)

SECOND AMENDMENT TO MASTER LICENSE AGREEMENT (Filed With SEC on August 5, 2015)

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 5, 2015)

FIRST AMENDMENT TO MASTER LICENSE AGREEMENT (Filed With SEC on October 31, 2014)

LIGANDPHARMACEUTICALS INCORPORATED AS ISSUER 0.75% CONVERTIBLE SENIOR NOTES DUE 2019 INDENTURE DATED AS OF AUGUST 18, 2014 WILMINGTON TRUST, NATIONAL ASSOCIATION AS TRUSTEE TABLE... (Filed With SEC on August 18, 2014)

LOAN AND SECURITY AGREEMENT (Filed With SEC on August 5, 2014)

MASTER LICENSE AGREEMENT Dated May 21, 2014 by and between Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc., on one hand, and Viking Therapeutics, Inc., on the... (Filed With SEC on August 5, 2014)

RESEARCH AND LICENSE AGREEMENT Dated as of May 9, 2014 by and between Ligand Pharmaceuticals Incorporated and Omthera Pharmaceuticals, Inc. RESEARCH AND LICENSE AGREEMENT (Filed With SEC on August 5, 2014)

LICENSE AGREEMENT Dated as of June 23, 2014 by and between Ligand Pharmaceuticals Incorporated and TG Therapeutics, Inc. LICENSE AGREEMENT (Filed With SEC on August 5, 2014)

AMENDMENT OF GENERAL CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on May 22, 2014)

AMENDMENT OF TR BETA CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on May 22, 2014)

LIGAND PHARMACEUTICALS INCORPORATED NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on February 24, 2014)

LICENSE AGREEMENT (Filed With SEC on November 8, 2013)

RECITALS: (Filed With SEC on November 8, 2013)

LICENSE AGREEMENT BETWEEN CYDEX PHARMACEUTICALS, INC. AND CURX PHARMACEUTICALS, INC. DATED: August 12, 2013 TABLE OF CONTENTS (Filed With SEC on November 8, 2013)

SUPPLY AGREEMENT BETWEEN CYDEX PHARMACEUTICALS, INC. AND CURX PHARMACEUTICALS, INC. DATED: August 12, 2013 TABLE OF CONTENTS (Filed With SEC on November 8, 2013)

LIGAND PHARMACEUTICALS INCORPORATED Common Stock (par value $0.001 per share) At the Market Issuance Sales Agreement (Filed With SEC on October 16, 2013)

LIGAND PHARMACEUTICALS INCORPORATED DOCS ATM financing facility $24,000,000 of Common Stock, $0.001 par value SALES AGREEMENT October 11, 2013 (Filed With SEC on October 16, 2013)

ROYALTY STREAM AND MILESTONE PAYMENTS PURCHASE AGREEMENT (Filed With SEC on August 1, 2013)

FIRST AMENDMENT TO 2006 PREFERRED SHARES RIGHTS AGREEMENT June 19, 2013 (Filed With SEC on June 20, 2013)

LICENSE AGREEMENT (Filed With SEC on May 8, 2013)

SUPPLY AGREEMENT (Filed With SEC on May 8, 2013)

SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on March 25, 2013)

AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on March 14, 2013)

RESEARCH LICENSE AND OPTION AGREEMENT Dated April 27, 2012 By and Between Ligand Pharmaceuticals Incorporated and Ares Trading SA (Filed With SEC on August 8, 2012)

SEPARATION AGREEMENT (Filed With SEC on August 8, 2012)

SUBLICENSE AGREEMENT (Filed With SEC on May 4, 2012)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 4, 2012)

LIGAND PHARMACEUTICALS INCORPORATED Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on March 26, 2012)

JOINDER AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 23, 2012)

LICENSE AGREEMENT BETWEEN CYDEX PHARMACEUTICALS, INC. AND ELI LILLY AND COMPANY DATED: December 16, 2011 TABLE OF CONTENTS (Filed With SEC on February 23, 2012)

SUPPLY AGREEMENT BETWEEN CYDEX PHARMACEUTICALS, INC. AND ELI LILLY AND COMPANY DATED: December 16, 2011 TABLE OF CONTENTS (Filed With SEC on February 23, 2012)

LICENSE AND SUPPLY AGREEMENT (Filed With SEC on February 23, 2012)

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 23, 2012)

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on January 26, 2012)

SECURED PROMISSORY NOTE (Filed With SEC on January 26, 2012)

FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on November 8, 2011)

LEASE AGREEMENT (Filed With SEC on September 9, 2011)

LICENSE AGREEMENT (Filed With SEC on September 9, 2011)

LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCKOWNERSHIP POLICY (Amended and Restated Effective June 1, 2011) I. DIRECTOR COMPENSATION (Filed With SEC on August 8, 2011)

LICENSE AGREEMENT (Filed With SEC on August 8, 2011)

SUPPLY AGREEMENT (Filed With SEC on August 8, 2011)

LICENSE AGREEMENT (Filed With SEC on May 10, 2011)

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 29, 2011)

LIGAND PHARMACEUTICALS, INCORPORATED LOAN AND SECURITY AGREEMENT (Filed With SEC on April 4, 2011)

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)

2nd Amendment to the CAPTISOL® SUPPLY AGREEMENT dated as of December 20, 2002 and amended July 29, 2005 BY AND BETWEEN CYDEX, INC. AND THE HOVIONE GROUP Dated as of March 1, 2007... (Filed With SEC on March 3, 2011)

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)

AMENDMENT OF GENERAL CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 31, 2011)

CERTIFICATE OF MERGER OF CAYMUS ACQUISITION, INC. (a Delaware corporation) WITH AND INTO CYDEX PHARMACEUTICALS, INC. (a Delaware corporation) Pursuant toSection 251 of the General... (Filed With SEC on January 26, 2011)

AGREEMENT AND PLAN OF MERGER by and among: LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation; CAYMUSACQUISITION, INC., a Delaware corporation; and CYDEX PHARMACEUTICALS,... (Filed With SEC on January 26, 2011)

CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 26, 2011)

LOAN AND SECURITY AGREEMENT (Filed With SEC on January 26, 2011)

ASSET PURCHASE AGREEMENT Dated as of July 30, 2010 By and Between WYETH LLC and PHARMACOPEIA, INC. and Solely for Purposes of the Specified Sections Herein LIGAND PHARMACEUTICALS... (Filed With SEC on November 9, 2010)

PURCHASE AGREEMENT BETWEEN BIOTECHNOLOGY VALUE FUND, L.P., ON ITS OWN BEHALF AND ON BEHALF OF BIOTECHNOLOGY VALUE FUND II, L.P. AND INVESTMENT 10, L.L.C. and LIGAND... (Filed With SEC on August 5, 2010)

PURCHASE AND SALE AGREEMENT (Filed With SEC on May 24, 2010)

AMENDMENT NUMBER ONE TO RESEARCH AND LICENSE AGREEMENT (Filed With SEC on May 3, 2010)

AMENDMENT (Filed With SEC on March 3, 2010)

CERTIFICATE OF MERGER OF (Filed With SEC on January 28, 2010)

CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 28, 2010)

CERTIFICATE OF MERGER OF (Filed With SEC on December 24, 2009)

CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on December 24, 2009)

AMENDMENT NO. 3 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on December 17, 2009)

AMENDMENT TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on December 1, 2009)

RESEARCH COLLABORATION TERMINATION AGREEMENT (Filed With SEC on November 9, 2009)

AMENDMENT NO. 2 TO PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on November 9, 2009)

AMENDMENT TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on November 6, 2009)

AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on November 6, 2009)

by and among: LIGAND PHARMACEUTICALSINCORPORATED, a Delaware corporation; MOONSTONE ACQUISITION, INC., a Delaware corporation; METABASIS THERAPEUTICS,INC., a Delaware corporation;... (Filed With SEC on October 28, 2009)

Form of Roche CVR Agreement CONTINGENT VALUERIGHTS AGREEMENT (Filed With SEC on October 28, 2009)

Form of TR Beta CVR Agreement CONTINGENT VALUERIGHTS AGREEMENT (Filed With SEC on October 28, 2009)

Form of Glucagon CVR Agreement CONTINGENT VALUERIGHTS AGREEMENT (Filed With SEC on October 28, 2009)

Form of General CVR Agreement CONTINGENT VALUERIGHTS AGREEMENT (Filed With SEC on October 28, 2009)

VOTING AGREEMENT (Filed With SEC on October 28, 2009)

AGREEMENT AND PLAN OF MERGER by and among: LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation; NEON SIGNAL, LLC, (Filed With SEC on August 24, 2009)

Form of Aplindore CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on August 24, 2009)

Form of H3 CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on August 24, 2009)

Form of Merck CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on August 24, 2009)

Form of Real Estate CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on August 24, 2009)

VOTING AGREEMENT (Filed With SEC on August 24, 2009)

LEASE HCP TPSP, LLC Landlord AND (Filed With SEC on August 11, 2009)

LEASE TERMINATION AGREEMENT (Filed With SEC on August 11, 2009)

1 of 19 (Filed With SEC on August 4, 2009)

LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective April 16, 2009) I. DIRECTOR COMPENSATION (Filed With SEC on August 4, 2009)

ARTICLE 1 DEFINITIONS (Filed With SEC on May 11, 2009)

SEPARATION AGREEMENT (Filed With SEC on May 11, 2009)

PHARMACOPEIA, INC. 2000 STOCK OPTION PLAN (Filed With SEC on March 16, 2009)

By and Between PHARMACOPEIA, INC. and SCHERING-PLOUGH LTD. Table of Contents i COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 16, 2009)

By and Between PHARMACOPEIA, INC. and SCHERING CORPORATION Table of Contents i COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 16, 2009)

LEASE AGREEMENT BY AND BETWEEN: Eastpark at 8A Landlord (Filed With SEC on March 16, 2009)

ARTICLE 1 DEFINITIONS (Filed With SEC on March 16, 2009)

CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on December 24, 2008)

LIGAND PHARMACEUTICALS INCORPORATED AMENDED AND RESTATED SEVERANCE PLAN (AND SUMMARY PLAN DESCRIPTION) (Filed With SEC on December 24, 2008)

SETTLEMENT AGREEMENT AND MUTUAL RELEASE OF ALL CLAIMS (Filed With SEC on November 7, 2008)

AGREEMENT AND PLAN OF MERGER (Filed With SEC on September 26, 2008)

CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on September 26, 2008)

LIGAND PHARMACEUTICALS INCORPORATED 2002 STOCK INCENTIVE PLAN (Filed With SEC on March 5, 2008)

AMENDMENT TO RESTRICTED STOCK AGREEMENT (Filed With SEC on March 5, 2008)

Exhibit No (Filed With SEC on December 19, 2007)

No information provided due to inapplicability of item (Filed With SEC on August 8, 2007)

Approved in March 2002 for sale in the U.S. for the once-daily treatment of moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an... (Filed With SEC on March 16, 2007)

No information provided due to inapplicability of item (Filed With SEC on November 14, 2006)

PURCHASE AGREEMENT AND ESCROW INSTRUCTIONS (Filed With SEC on October 31, 2006)

No information provided due to inapplicability of item (Filed With SEC on August 9, 2006)

SEPARATION AGREEMENT (Filed With SEC on August 4, 2006)

RELEASE OF CLAIMS (Filed With SEC on August 4, 2006)

No information provided due to inapplicability of item (Filed With SEC on May 15, 2006)

Common stock offered (Filed With SEC on February 10, 2006)

Common stock offered (Filed With SEC on January 13, 2006)

No information provided due to inapplicability of item (Filed With SEC on December 9, 2005)

Category

Industry

Companies

Contracts

Ligand Pharmaceuticals Incorporated Contracts & Agreements